J Buter
Overview
Explore the profile of J Buter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
681
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Beek F, Jansen F, Mak L, Lissenberg-Witte B, Buter J, Vergeer M, et al.
Oral Oncol
. 2020 Feb;
102:104576.
PMID: 32028135
Objectives: To identify sociodemographic and clinical factors, health-related quality of life (HRQOL) and head and neck cancer (HNC) symptoms associated with the course of symptoms of anxiety and depression from...
2.
Melissant H, Jansen F, Schutte L, Lissenberg-Witte B, Buter J, Leemans C, et al.
Oral Oncol
. 2018 Aug;
83:120-126.
PMID: 30098767
Introduction: The aim of this prospective study was to investigate the course of sexual interest and enjoyment in relation to sociodemographic and clinical factors, health-related quality of life (HRQOL), and...
3.
Specenier P, Remenar E, Buter J, Schrijvers D, Bergamini C, Licitra L, et al.
Ann Oncol
. 2017 Sep;
28(9):2219-2224.
PMID: 28911062
Background: Our aim was to test the safety of cetuximab added to chemoradiation with either cisplatin or carboplatin after prior induction chemotherapy. Methods: Patients with stage III/IV unresectable, squamous cell...
4.
Holla F, Postma T, Blankenstein M, van Mierlo T, Vos M, Sizoo E, et al.
J Neurooncol
. 2016 Jul;
129(3):525-532.
PMID: 27401156
The S100B protein is associated with brain damage and a breached blood-brain barrier. A previous pilot study showed that high serum levels of S100B are associated with shorter survival in...
5.
Putten L, Bree R, Doornaert P, Buter J, Eerenstein S, Rietveld D, et al.
Acta Otorhinolaryngol Ital
. 2015 Aug;
35(3):162-72.
PMID: 26246660
Our objective was to evaluate recurrence patterns of hypopharyngeal and laryngeal carcinoma after chemoradiation and options for salvage surgery, with special emphasis on elderly patients. In a retrospective study all...
6.
Van der Linden N, van Gils C, Pescott C, Buter J, Vergeer M, Uyl-de Groot C
Eur Arch Otorhinolaryngol
. 2014 Jun;
272(8):2007-16.
PMID: 24943191
Clinical trial EMR 62202-006 demonstrates prolonged median locoregional control (24.4 vs. 14.9 months), progression-free survival (17.1 vs. 12.4 months) and overall survival (49.0 vs. 29.3 months) for patients who receive...
7.
Froklage F, Oosterbaan L, Sizoo E, de Groot M, Bosma I, Sanchez E, et al.
J Neurooncol
. 2013 Nov;
116(2):387-94.
PMID: 24264531
Following tumor resection, the majority of high-grade glioma (HGG) patients are treated with a combined modality regimen of radiotherapy and temozolomide. As a result of the tumor itself or as...
8.
Van der Linden N, van Gils C, Pescott C, Buter J, Uyl-de Groot C
Eur Arch Otorhinolaryngol
. 2013 Aug;
271(6):1673-8.
PMID: 23907370
In a randomized controlled trial in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), treatment with RT plus cetuximab resulted in improved survival compared...
9.
Karagozoglu K, Buter J, Leemans C, Rietveld D, van den Vijfeijken S, van der Waal I
Br J Oral Maxillofac Surg
. 2011 Oct;
50(6):513-8.
PMID: 22000636
Oral verrucous carcinoma (OVC) is a low-grade variant of squamous cell carcinoma (SCC) with a distinctive morphology and specific pattern of behaviour that is often diagnosed in elderly patients. Resection...
10.
Garrett C, Siu L, El-Khoueiry A, Buter J, Rocha-Lima C, Marshall J, et al.
Br J Cancer
. 2011 Jun;
105(1):44-52.
PMID: 21629245
Background: The objectives of this phase I study were to determine the safety, pharmacokinetics (PK), pharmacodynamics and efficacy of brivanib combined with full-dose cetuximab in patients with advanced gastrointestinal malignancies....